Morningstar

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and ...
Business Wire

Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause

Christian Seitz Thursday, September 12, 06:15 PM to 7:15 PM CT, Location: Riverside East, Riverside West/South – Exhibit Hall Level- East Tower Poster #122: “Do sleep disturbances have an impact on ...
FierceBiotech

Boehringer and Bayer's oral meds deliver in early HER-2 mutant lung cancer studies

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor 2 (HER2), which drives their disease progression. Treatment options are ...
Barron's

Bayer In $1.3 Bn Deal For Cancer Drug Candidate

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug. The ...
GEN

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering ...
Hosted on MSN

Bayer to Pay $1.3 Billion for Cancer Medicine in Pharma Push

(Bloomberg) -- Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its pharma division’s growth prospects. The German company will ...
Reuters

Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal

BERLIN, Aug 12 (Reuters) - German pharmaceutical group Bayer (BAYGn.DE), opens new tab announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology ...
FiercePharma

As Xarelto's decline picks up speed, Bayer doesn't expect pharma growth until 2027

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the company’s pharma division was able to eke out modest sales gains of 1.7% in the ...